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Abstract
Due to a harsh environment mitochondrial genomes accumulate high levels of DNA damage, in
particular oxidation, hydrolytic deamination, and alkylation adducts. While repair of alkylated
bases in nuclear DNA has been explored in detail, much less is known about the repair of DNA
alkylation damage in mitochondria. Alkyladenine DNA glycosylase (AAG) recognizes and
removes numerous alkylated bases, but to date AAG has only been detected in the nucleus, even
though mammalian mitochondria are known to repair DNA lesions that are specific substrates of
AAG. Here we use immunofluorescence to show that AAG localizes to mitochondria, and we find
that native AAG is present in purified human mitochondrial extracts, as well as that exposure to
alkylating agent promotes AAG accumulation in the mitochondria. We identify mitochondrial
single-stranded binding protein (mtSSB) as a novel interacting partner of AAG; interaction
between mtSSB and AAG is direct and increases upon methyl methanesulfonate (MMS)
treatment. The consequence of this interaction is specific inhibition of AAG glycosylase activity
in the context of a single-stranded DNA (ssDNA), but not a double-stranded DNA (dsDNA)
substrate. By inhibiting AAG-initiated processing of damaged bases, mtSSB potentially prevents
formation of DNA breaks in ssDNA, ensuring that base removal primarily occurs in dsDNA. In
summary, our findings suggest the existence of AAG-initiated BER in mitochondria and further
support a role for mtSSB in DNA repair.
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1. Introduction
The human mitochondrial genome comprises 16,569 DNA base pairs, organized in a
circular, double-stranded DNA (dsDNA) molecule. In vivo two to eight mitochondrial DNA
(mtDNA) molecules are held together in a protein-DNA complex known as the
mitochondrial nucleoid [1]. Proteins involved in nucleoid formation include mitochondrial
single-stranded binding protein (mtSSB), DNA polymerase (pol)!, mtDNA helicase
(Twinkle) and mitochondrial transcription factor A (TFAM) [2, 3]. Similar to the nuclear
genome, mtDNA is continuously exposed to various DNA damaging agents. Due to high
levels of reactive oxygen species (ROS) generated within mitochondria, frequently
occurring DNA lesions include products of oxidation and hydrolytic deamination, as well as
exocyclic adducts, like 1,N6-ethenoadenine (!A), formed indirectly through lipid
peroxidation [4-6]. In comparison to the nuclear genome, mtDNA accumulates more
damage after treatment with alkylating or oxidative agents [7-11]. The importance of
mtDNA maintenance is clearly demonstrated by numerous findings associating mutations in
the mitochondrial genome with a plethora of human pathologies [12, 13]. In addition to
giving rise to inherited diseases [12, 14], mutations in mtDNA have been strongly linked to
cancer, aging and diabetes [15-17].
To prevent accumulation of small DNA base lesions, cells utilize the base excision repair
(BER) pathway. DNA glycosylases determine the specificity of this pathway by recognizing
and excising specific damaged bases, generating an abasic (AP) site that is processed by the
apurinic/apyrimidinic endonuclease 1 (APE1); the resulting gap is filled and sealed by DNA
pol and DNA ligase, respectively [18-20]. To date six DNA glycosylases are known to
localize in mitochondria; 8-oxoguanine DNA glycosylase (OGG1), MutY homologue
(MutYH), uracil DNA glycosylase 1 (UNG1), Nth endonuclease III-like 1 (NTH1) and two
endonuclease VIII homologs (NEIL1 and NEIL2) [21-29]. These DNA glycosylases process
a variety of DNA base lesions, including 7,8-dihydro-8-oxo-2′deoxyguanine (8-oxo-G),
uracil (U) and 5-hydroxyuracil (5OHU).
The DNA glycosylase that usually recognizes and excises alkylated and deaminated bases
from DNA is the alkyladenine DNA glycosylase (AAG) [30]. Gene encoding human AAG
is positioned on the short arm of the chromosome 16 and comprises five exons, of which
two (1a and 1b) are localized in the promoter region [31]. Since the promoter activity has
been detected only upstream of exon 1a and not in the DNA region between the two exons,
it is suggested that three distinct mRNA forms of human AAG, are formed through post-
transcriptional processing [32]. Isoform A is the longest transcript; isoform B lacks an exon
in the 5′ region and is translated from an alternative start codon [31, 33, 34]. Isoform C is
the shortest transcript variant that is missing part of the 5′coding region and is translated
from a downstream in-frame start codon [35]. AAG has a unique ability among DNA
glycosylases to act on several structurally diverse bases within dsDNA, such as: 3-
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methyladenine, 7-methyguanine, hypoxanthine (Hx), !A, 1-methylguanine, 1,N2-
ethenoguanine and U [35-39]. Besides lesions in dsDNA, AAG can also remove !A and Hx
from single-stranded DNA (ssDNA), thereby creating AP sites that could potentially give
rise to harmful DNA breaks [37]. To our knowledge, AAG has not previously been detected
in the mitochondria, despite the fact that mammalian mitochondria have been shown to
repair DNA lesions that are specific substrates of AAG [40-42].
In addition to the major BER enzymes, several auxiliary proteins have been implicated in
mitochondrial BER, such as mtSSB and TFAM. Both mtSSB and TFAM inhibit removal of
the damaged bases from mtDNA [43, 44]. The presence of mtSSB impairs UNG1 mediated
excision of U and 5OHU from ssDNA [44]. MtSSB also inhibits ssDNA nicking by APE1
[44]. Besides potential involvement in DNA repair, the primary role of mtSSB is in mtDNA
replication, during which it stimulates the activity of DNA pol ! and helicase Twinkle, as
well as influencing displacement-loop (D-loop) turnover [45-49]. The D-loop is a triple
stranded structure generated during strand displacement mtDNA replication [50, 51]. The
consequence of such strand-asymmetric DNA synthesis is that one of the newly synthetized
mitochondrial genomes contains large ssDNA regions [52-55]. Binding of the mtSSB
homotetramer to ssDNA is of crucial importance to ensure genomic stability and to prevent
formation of highly toxic and mutagenic DNA lesions, such as DNA breaks [56, 57].
Although mtSSB inhibits removal of U and 5OHU from ssDNA, thus preventing subsequent
formation of DNA breaks, it is not clear whether this effect is UNG1 specific, or if mtSSB
plays a more general role in inhibiting mitochondrial BER initiation by influencing other
DNA glycosylases.
Here we analyzed the localization of human AAG in different cellular compartments. In
addition to the nucleus and cytoplasm, we detected AAG in the mitochondria. Exposure to
methyl methanesulfonate (MMS) promoted mitochondrial accumulation of AAG. Software
analysis identified potential mitochondrial targeting signal (MTS) in two of the three known
AAG isoforms, further supporting our finding that AAG localizes in the mitochondria. To
explore which mitochondrial proteins associate with AAG, we performed liquid
chromatography-mass spectrometry (LC-MS) and identified mtSSB in complex with AAG.
We confirmed direct physical interaction between AAG and mtSSB, and observed that the
extent of interaction is dependent on MMS treatment. Finally we demonstrate that mtSSB
significantly dampens AAG activity in the context of ssDNA, but does not affect AAG
mediated processing of damaged substrate in dsDNA. MtSSB thus potentially regulates
AAG activity in mitochondria by: (i) preventing AAG-mediated removal of alkylation
damage from ssDNA, thus averting the formation of extremely harmful DNA breaks; and
(ii) ensuring that AAG-mediated processing of DNA base lesions takes place only upon
reestablishment of dsDNA. In summary, our findings suggest the existence of AAG in the
mitochondria and further support an important role of mtSSB in mtDNA repair.
2. Material and Methods
2.1. Chemicals
Labeled ! [32P] ATP was purchased from Perkin Elmer and Hartmann Analytic. All the
other reagents were of analytical grade and purchased from Merck, Sigma or Fluka. The
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undamaged 39-mer and complementary 16-mer oligonucleotides were purchased from
Microsynth.
2.2. Oligonucleotide DNA Substrates
16-mer oligonucleotide containing !A lesion or undamaged A was kindly provided by Prof.
John M. Essigman. Synthesis of these oligonucleotides was performed as described
previously [58]. The sequence of the 16-mer oligonucleotide containing !A lesion or
undamaged A is depicted in the Fig. 4A. The control 39-mer oligonucleotide sequence was
published before [59]. Primers were 5′-labeled with ![32P] ATP using T4 polynucleotide
kinase (New England Biolabs), according to the manufacturer's protocol. For experiments
involving dsDNA substrates, complementary 16-mer oligonucleotides were annealed using a
1:1.5 ratio of modified to unlabeled complement. As a base opposite !A lesion was chosen
thymine (T), the base-paring partner of the undamaged base.
2.3. Cells and cell treatments
Human HEK293T and HeLa CCL2 cells were purchased from American Tissue Type
Culture Collection and grown in a humidified 5% CO2 atmosphere in DMEM containing
GlutaMAX-I supplemented with 10% FBS and 100U/ml penicillin-streptomycin (all
obtained from Gibco, Invitrogen).
Treatment of cells with alkylating agent was achieved by incubation for 1h at 37°C in
serum-free DMEM containing 2mM MMS or serum-free medium alone (mock treatment).
Double thymidine block was accomplished by seeding HeLa CCL2 cells in six-well plates
containing complete DMEM medium for 8h, after which medium with 2mM thymidine was
added and cells incubated for 16h. Cells were next washed with phosphate-buffered saline
(PBS) and incubated for 8h in fresh medium, followed by second 16h incubation in medium
with 2mM thymidine. Synchronization of cells at G1/S boundary was confirmed by
fluorescence activated cell sorting analysis as described before [59].
2.4. Whole cell extracts
Cells were trypsinized, washed twice with cold PBS and resuspended in two packed cell
volumes (PCV) of hypotonic lysis buffer (20mM HEPES at pH7.9, 2mM MgCl2, 0.2mM
EGTA, 10% (v/v) glycerol, 0.1mM PMSF, 2mM DTT) complemented with Halt Protease
and Phosphatase Inhibitors Single-Use Cocktail without EDTA (Thermo Scientific). After
swelling for 5min at 4°C, cells were lysed by three freeze/thaw cycles. NaCl and Nonidet-
P40 were added next to a final concentration 0.5M and 0.5% (v/v), respectively and
incubated 20min at 4°C. Samples were diluted with eight PCV of lysis buffer containing
50mM NaCl, sonicated and centrifuged. The supernatants were flash frozen in liquid N2 or
analyzed directly.
2.5. Isolation of mitochondria from HEK293T cells
Human mitochondria were isolated from HEK293T cells according to a well-established
protocol [60]. Briefly, 2mM MMS or mock treated cells were harvested and washed twice
with cold PBS. Cell pellet was resuspended in six PCV of homogenization medium (10mM
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Tris-HCl at pH 6.7, 0.15mM MgCl2, 10mM KCl) and homogenized using a tightly fitting
Dounce homogenizer. The homogenate was complemented with two PCV of
homogenization medium containing 1M sucrose and nuclei were pelleted by centrifugation
5min at 1000g, 4°C. The pellet was washed in homogenization medium, centrifuged and
nuclear extract prepared by the addition of TXIP buffer (10mM Tris-HCL at pH 7.8,
150mM NaCl, 1% Triton X-100, 1mM EDTA, 1mM DTT, 0.25mM PMSF, 10% (v/v)
glycerol). The supernatant obtained upon pelleting of nuclei was transferred to a fresh tube
and centrifuged a second time for 10min at 5000g, 4°C. The supernatant was collected,
representing the cytoplasmic fraction, while the pellet was resuspended in sucrose/Mg2+
medium (10mM Tris-HCl at pH 6.7, 0.15mM MgCl2, 0.25M sucrose) and centrifuged for
10min at 5000g, 4°C. The pelleted mitochondria were resuspended in TXIP buffer. All
protein concentrations were determined by BioRad assay using BSA as standard.
2.6. Mitochondrial trypsin digestion
After centrifugation in sucrose/Mg2+ medium, purified mitochondria were treated with 1, 5
and 10 μg/ml trypsin (Sigma) in 100μl of digestion medium (10mM Tris-HCl at pH 7.4,
0.1mM EGTA, and 0.25M sucrose) for 1h at 4 °C. The reaction was stopped by addition of
50μg Leupeptin and the mitochondria were centrifuged at 18000g for 5 min. Mitochondrial
extracts were obtained by resuspending pellet in TXIP buffer, loaded on an SDS-PAGE gel
and subjected to immunoblot analysis.
2.7. Protein analysis
Purified protein samples, nuclear, mitochondrial, cytoplasmic and whole cellular extracts
were separated on 4–12% Bis–Tris polyacrylamide gels (Invitrogen) followed by transfer to
Immobilon-FL membrane (Millipore) for immunoblotting or silver staining (SilverQuest
Kit, Invitrogen). Primary antibodies against the FLAG tag (F1804, Sigma), mtSSB
(ab74710, Abcam), AAG (rabbit polyclonal antibody generated in our laboratory; or
sc-101237, Santa Cruz), PCNA (sc-56, Santa Cruz), GAPDH (sc-69778, Santa Cruz), Lamin
B (101-B7, Calbiochem), VDAC1 (sc-32063, Santa Cruz), Mitofilin (ab110329, Abcam)
and mtHSP70 (ab2799, Abcam) were detected using infrared (IR) Dye-conjugated
secondary antibodies (Rockland). The signal was visualized using direct IR fluorescence via
the Odyssey Scanner (LI-COR Biosciences).
2.8. Microscopy
HeLa CCL2 cells were grown on glass coverslips and synchronized by double thymidine
block. Upon release cells were incubated for 30min at 37°C in DMEM medium containing
100nM CMXRos-MitoTracker (Invitrogen). Cells were then washed with PBS and mock or
MMS treated for 1h at 37°C. After the treatment cells were allowed to recover for 1h at
37°C in full medium. Treated cells were fixed with 3.7% paraformaldehyde for 10min and
permeabilized with 0.1% Triton in 1× CSK buffer (100mM NaCl, 300mM sucrose, 10mM
PIPES, 3mM MgCl2, 1mM EGTA) for 15min at room temperature. To block non-specific
binding samples were incubated with 4%BSA in PBS with 0.1% Nonidet-P40 for 1h at
37°C. Primary AAG antibody (HPA006531, Sigma) diluted 1:60 in PBS was added to
samples and incubated over-night at 4°C. After extensive washing, samples were incubated
with fluorophore-conjugated secondary antibody (ab6717, Abcam) at room temperature for
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2h. After washing off the unbound antibody ProLong Gold Antifade reagent (Invitrogen)
was used according to the manufacturers protocol. Images were captured with the Nikon
eclipse E800 with attached Qimaging retina exi fast 1394 camera.
2.9. Expression and purification of human ! 80AAG, ! 16mtSSB, Cdk1 and PCNA
Human recombinant !80AAG protein was expressed and purified as described previously
[61]. The first 80 amino acids were deleted from the N-terminus to facilitate protein
purification. ! 80AAG is a well-characterized variant of AAG, with a catalytic activity very
similar to that of the full-length protein [35, 61]. To express human mtSSB protein,
Escherichia coli BL21(DE3) strain (Novagen) was transfected with pET21aHmtSSB
construct, encoding human mtSSB protein, lacking 16 N-terminal amino acids. The
expression construct was a kind gift from Dr. William C. Copeland (NIEHS, USA).
Expression and purification were performed according to previously established protocol
[62]. Deletion of 16 amino acids, encoding mitochondrial targeting signal, from the N-
terminus of mtSSB was shown not to affect mtSSB properties, such as tetramerisation and
binding of ssDNA [62]. The protein concentrations depicted in different figures of this
manuscript are calculated for mtSSB as a tetrameric protein. Human PCNA and Cdk1 have
been expressed and purified as described previously [63, 64].
2.10. Expression and purification of human full-length AAG
The coding region of full-length human AAG (NCBI: NP_002425.2) was amplified and
cloned into a modified pcDNA3.1 vector (Invitrogen) containing a triple Flag-streptavidin
binding peptide fusion protein [65], resulting in N-terminally Flag-Tag fused AAG
expression construct. Empty pcDNA3.1-Flag or pcDNA3.1-FlagAAG expression constructs
(0.1! g/ml) were transiently transfected into 293T human embryonic kidney cells by calcium
phosphate precipitation. Before harvesting, cells were mock treated or treated with 2mM
MMS for 1h and whole cell extracts were prepared. Whole cell extracts (1mg total protein)
were incubated with 20! l of FLAG M2 antibody resin (Sigma) for 2h at 4°C in wash buffer
(20mM HEPES at pH7.9, 2mM MgCl2, 0.2mM EGTA, 10% (v/v) glycerol, 0.1mM PMSF,
2mM DTT, 140mM NaCl, 0.01% (v/v) Nonidet-P40). The resin was washed four times
using the same buffer. Bound samples were eluted in two steps with wash buffer containing
100! g/mL 3×Flag peptide (Sigma) and flash frozen in liquid N2 or subjected to
trichloroacetic acid precipitation.
2.11. Protein mass spectrometry
Protein identification was performed by the Biopolymers and Proteomics Core Facility of
the David H. Koch Institute for Integrative Cancer Research (http://ki.mit.edu/sbc/
biopolymers). Briefly, protein samples were reduced, alkylated, and digested with trypsin,
followed by purification and desalting on an analytical C18 column tip. Processed peptides
were analyzed by chromatography on an Agilent Model 1100 Nanoflow high-pressure liquid
chromatography (HPLC) system coupled with electrospray ionization on a Thermo Electron
Model LTQ Ion Trap mass spectrometer. Scaffold (version Scaffold_3_00_04, Proteome
Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein
identifications. Peptide identifications were accepted if they could be established at greater
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than 95.0% probability as specified by the Peptide Prophet algorithm [66]. Peptide
identifications were also required to exceed specific database search engine thresholds.
SEQUEST [67] identification required spectra to match full tryptic peptides of at least 7
amino acids, have a normalized difference in cross-correlation scores (ΔCn) of at least 0.1,
and have minimum cross-correlation scores (Xcorr) of greater than 2.0, 2.5, 3.5 and 3.5 for
singly, doubly, triply and quadruply charged peptides. Protein identifications were accepted
if they could be established at greater than 99.0% probability and contained at least 2
identified peptides.
2.12. Immunoprecipitation
Whole cell extracts (0.5mg of total protein) were incubated with 2! g of AAG antibody
(sc-101237, Santa Cruz) or normal mouse IgG (sc-2343) at 4°C over night. Protein A
Dynabeads (Invitrogen) were equilibrated in the wash buffer (20mM HEPES at pH7.9, 2mM
MgCl2, 0.2mM EGTA, 10% (v/v) glycerol, 0.1mM PMSF, 2mM DTT, 140mM NaCl,
0.01% (v/v) Nonidet-P40) and blocked at 4°C over night in a wash buffer containing 1%
BSA. After three consecutive washes using wash buffer, beads were added to samples
containing WCE and antibody; and incubated for 4,5h at 4°C. The supernatant was removed
and beads washed three times with cold wash buffer. Beads were boiled in Laemmli sample
loading buffer, resolved on 4-12% SDS-PAGE gel and subjected to immunoblot analysis.
2.13. Far Western Blotting
Detection of protein-protein interactions by far western blotting was performed according to
a previously established protocol [68]. Briefly, purified recombinant ! 80AAG, His tagged !
16mtSSB, BSA, GST tagged Cdk1 and His tagged PCNA (1! g) were separated by SDS-
PAGE and transferred onto a polyvinylidene fluoride (PVDF) membrane. Membranes were
then briefly stained by Ponceau to ensure equal loading, followed by destaining. Proteins
were denatured and renatured in situ in AC buffer (10% (v/v) glycerol, 100mM NaCl,
20mM Tris at pH 7.5, 1mM EDTA, 0.1% (v/v) Tween-20, 2% (w/v) milk, 1mM DTT) by
gradually reducing the guanidine-HCl concentration from 6M to 0M. Renatured membranes
were blocked with 5% milk in PBST, followed by incubation with purified interacting (bait)
protein ! 80AAG or ! 16mtSSB, as indicated in Fig. 3 legends, at a concentration of 1! g/ml
in PB buffer (20mM HEPES at pH7.9, 2mM MgCl2, 10% (v/v) glycerol, 0.1mM PMSF,
1mM DTT, 130mM NaCl, 0.01% (v/v) Nonidet-P40), overnight at 4°C. To ensure
specificity of obtained results in the negative control samples 1! g/ml of BSA was added to
PB buffer and incubated with membrane overnight at 4°C. Unbound protein was removed in
four washing steps using PB buffer. In the second wash PB buffer was complemented with
0.0001% (v/v) glutaraldehyde. From this point a conventional immunoblot analysis was
performed with the respective antibodies.
2.14. DNA Glycosylase Assay
For denaturing gel analysis of DNA glycosylase products, the reaction mixture (10! l)
containing: 20mM Tris-HCl at pH7.8, 100mM KCl, 5mM 2-mercaptoethanol, 2mM EDTA,
1mM EGTA, 50! g/ml BSA and 2nM 32P-labelled DNA substrate was incubated with
200nM ! 80AAG. Amounts of recombinant BSA and human ! 16mtSSB were varied as
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indicated in the figure legends. In all DNA glycosylase assays an extensively characterized
form of AAG lacking the first 80 amino acids was used. The experiments were performed
under single-turnover conditions, with an enzyme concentration 100-fold higher than the
amount of labeled DNA oligonucleotide. Reaction mixtures were incubated 30min at 37°C.
For kinetics studies, an aliquot of the reaction mixture was removed for quenching 0, 5, 15,
30, 45, 60, 90, 120 and 180min after the initiation of the reaction. Reactions were quenched
with 0.2N NaOH and heated for 15 min at 75°C. Formamide loading buffer was added to
each sample and cleaved products resolved on a 20% denaturing polyacrylamide gel.
Products of the DNA glycosylase assay were visualized by PhosphorImager (Typhoon Trio,
GE Healthcare) and analyzed by ImageQuant and GelEval 1.35 scientific imaging software
(FrogDance Software, UK). Enzymatic rate constants were determined using GraphPad
Prisam (GraphPad Software, Inc., La Jolla, CA) by fitting the gel band intensities of single-
turnover kinetics experiments into OnePhase Exponential Association equitation:
(1)
where y is the amount of substrate cleaved at any particular time point, ymax represents the
maximum amount of cleaved substrate, t is time and kobs is the observed activity rate
constant.
2.15. Electrophoretic Mobility Shift Assay
The binding affinity of ! 80AAG and ! 16mtSSB was tested in a reactions containing 50mM
HEPES at pH7.5, 100mM NaCl, 1mM EDTA, 5mM DTT, 25! g/ml BSA, 9.5% (v/v)
glycerol and and 2nM 32P-labelled DNA. The amounts of recombinant human ! 80AAG
and ! 16mtSSB were as indicated in the figure legends. Reactions were incubated for 30min
at 4°C and directly loaded on a 6% nondenaturing polyacrylamide gel. The separated
products were visualized as described above for DNA glycosylase activity assay.
3. Results
3.1. Human AAG Localizes to the Mitochondria, Nucleus, and Cytoplasm, and its Cellular
Distribution is Affected by MMS Treatment
To determine localization of human AAG in different cellular compartments, we fractioned
human HEK293T cells. Immunoblot analysis of nuclear, cytoplasmic and mitochondrial
fractions, reveals that AAG is not only present in the nucleus and cytoplasm, but also
localizes to the mitochondria (Fig. 1A, lane 3). To confirm that AAG is present in the
mitochondria, and to ensure that the observed effect is not a result of mitochondrial
purification procedure, we performed a trypsin digestion assay (Fig. 1B). Treatment of
isolated mitochondria with increasing trypsin induces gradual degradation of the proteins
closest to mitochondrial surface, followed by degradation of proteins in the matrix. Though
increasing trypsin amount partially affects AAG levels, Fig. 1B clearly shows that under
conditions that induce complete disruption of outer and inter mitochondrial membrane
proteins, namely VDAC1 and Mitofilin respectively, portion of AAG persists in the
mitochondrial matrix fraction marked by the presence of mtHSP70 (Fig. 1B, lane 4).
Complete loss of AAG and mtHSP70 signal is observed only upon treatment of isolated
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mitochondria with SDS (Fig. 1B, lane 5). These findings indicate that the protease-resistant
AAG fraction resides in the mitochondria, while the fraction digested by trypsin is present in
the external mitochondrial compartments, and confirm the conclusion from Fig. 1A that
AAG is a mitochondrial protein. We next tested whether exposure to alkylating agent MMS
influences AAG protein levels in the mitochondria isolated from cells immediately upon the
treatment and at different times post treatment. Exposure to MMS induces a moderate
increase in mitochondrial AAG protein levels, directly after the treatment (Fig. 1C, lane 2
and Fig. 1D), suggesting that induction of DNA alkylation damage promotes rapid
accumulation of AAG. Similar to the effect observed in mitochondria, MMS treatment leads
to a slight increase in nuclear AAG levels, albeit with different kinetics; AAG reaches a
maximum 0.5h after the exposure (Fig. S1A and B). In contrast to the mitochondria and
nucleus, levels of AAG in the cytoplasm remain largely unchanged upon MMS exposure
(Fig. S1C and D). These findings are further supported by immunofluorescence analysis,
which indicates that, although the majority of AAG localizes in the nucleus, a portion of
AAG clearly localizes in the mitochondria (Fig. 1E). The amount of AAG signal in
mitochondria is further increased upon MMS treatment (Fig. 1F). As this is the first time
that localization of endogenous AAG has been observed in mitochondria, we next addressed
which of the three AAG isoforms has the potential to be targeted to this cellular
compartment. Three software programs; MitoProt II [69], PSORT II [70] and iPSORT [71]
predict that isoforms A and B most likely localize to the mitochondria (Table 1). MitoProt II
and iPSORT software further indicate that isoforms A and B could be synthesized as a
precursor containing a MTS of 17 and 12 amino acids, respectively (Table 1). Taken
together these data indicate that AAG has the potential to localize into mitochondria.
3.2. MtSSB is detected in complex with human AAG
To better understand the potential role of AAG in mitochondria we tested whether any of the
proteins known to localize in this cellular compartment associate with AAG. We expressed,
and tandem affinity purified, the Flag-tagged human AAG isoform A protein from untreated
or MMS treated HEK293T cells. This isoform was chosen since in silico analysis predicted
that it contains a MTS. In parallel, a mock purification was performed from cells transfected
with empty vector. Silver staining and immunoblot analysis indicate that tagged AAG was
present in the appropriate cells (Fig. 2A and B). The empty vector and AAG samples from
untreated and MMS treated cells were next subjected to LC-MS. PCNA, a known interacting
partner of AAG [72] was found specifically in both AAG containing samples (Fig. 2C).
Only one protein that localizes specifically in the mitochondria co-purified with AAG,
namely mtSSB (Fig. 2C). In contrast to PCNA, mtSSB peptides are detected only in the
MMS-pretreated cells (Fig. 2C). We infer either that AAG and mtSSB interact specifically
upon treatment with alkylating agent, or that in untreated cells the amount of mtSSB
associated with AAG is not detectable by LC-MS.
3.3. Human AAG and mtSSB Proteins Directly Interact
To address whether mtSSB and AAG can interact in the absence of DNA damaging agent,
and whether mtSSB and AAG interact under conditions when AAG is not ectopically
expressed, we performed AAG-immunoprecipitation assays using untreated, non-transfected
human cells. Incubation of the AAG antibody with whole cell extract resulted in the
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immunoprecipitation of mtSSB in complex with AAG (Fig. 3A, lane 2), thus indicating that
AAG and mtSSB form a complex at endogenous levels under normal conditions. We next
determined whether MMS exposure affects the intensity of interaction between these two
proteins. The highest level of mtSSB co-immunoprecipitating with AAG is observed
directly after the MMS treatment (Fig. 3A, lane 3), and this level diminishes with time (Fig.
3A, lanes 4-6). These results correlate well with the observed increase in the mitochondrial
AAG protein levels directly after MMS exposure (Fig. 1C and D). In addition, the stronger
interaction observed between AAG and mtSSB upon exposure to alkylation damage, may
explain why, by LC-MS, we only detected mtSSB in the fractions collected immediately
after MMS treatment and not in the untreated sample (Fig. 2C). To exclude the possibility
that the difference in the interaction intensity may be a consequence of changes in protein
levels, we analyzed whole cell extracts by immunoblot analysis; we did not detect any
significant changes in either mtSSB or AAG levels upon MMS treatment (Fig. S2). Since
endogenous AAG and mtSSB could potentially form a complex indirectly through a mutual
association with DNA, we next used far western blotting to determine whether mtSSB and
AAG interact directly. For these experiments we used two well-characterized truncated
recombinant protein forms ! 16mtSSB and ! 80AAG, neither of which contain a predicted
MTS, ensuring that the MTS could not mediate protein-protein interaction and that the
AAG/mtSSB complex could exist in the mitochondria. ! 80AAG, BSA as a negative control,
and the known mtSSB interacting partner Cdk1 [73], were immobilized on a PVDF
membrane (Fig 3B), followed by in situ renaturation. The membrane was then incubated
with a solution of 1! g/ml ! 16mtSSB, washed and any bound protein detected using mtSSB
antibody (Fig 3C). The presence of a mtSSB signal at the positions of ! 80AAG and Cdk1
indicates that ! 16mtSSB directly interacts with these two proteins (Fig 3C). Using a reverse
approach with ! 16mtSSB immobilized to PVDF membrane (Fig 3D), followed by
incubation with 1! g/ml ! 80AAG solution and protein detection with AAG antibody gave
similar result; AAG was detected at the position of ! 16mtSSB, as well as at the position of
PCNA, but not at the position of BSA (Fig 3E). These far western experiments with purified
proteins clearly show that AAG directly binds to mtSSB (Fig. 3C and E).
3.4. MtSSB Inhibits AAG Activity
Having shown that mtSSB and AAG directly interact, we went on to explore whether this
interaction affects AAG activity. We performed all experiments under single-turnover
conditions to ensure that a single AAG molecule binds and acts only once on damaged
DNA. We chose a ssDNA 16-mer oligonucleotide as a substrate (Fig. 4A). A short DNA
oligonucleotide was used to minimize binding of mtSSB to the substrate; human mtSSB is
known to cooperatively bind 50-70 nucleotides of DNA per tetramer [74]. The 16-mer AAG
oligonucleotide substrate contained an !A lesion (Fig. 4A), known to be induced in
mitochondria and to be linked to mitochondrial instability and apoptosis [4]. Upon titration
of ! 16mtSSB in the DNA glycosylase assay we observe that ! 16mtSSB inhibits ! 80AAG
mediated removal of ! A from ssDNA, when the amount of mtSSB is equal to the amount of
DNA glycosylase present in the reaction (Fig. 4B, compare lane 6 with 2). This effect is
statistically significant (Fig. 4C) and specific, since under the same conditions, titration of
BSA does not affect ! 80AAG glycosylase activity (Fig. S3). Finding that ! 16mtSSB
significantly inhibits ! 80AAG activity only when equal amounts of proteins are used,
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indicates that inhibition is potentially a result of direct protein-protein interaction. However,
it is formally possible that ! 16mtSSB binds to the short ssDNA under our assay conditions,
preventing DNA glycosylase from accessing the damaged base. To distinguish between the
two, and to confirm that mtSSB does not bind efficiently to the 16-mer ssDNA, we
performed electrophoretic mobility shift analysis. In agreement with previous findings
[75], ! 16mtSSB is fully functional and binds efficiently to 39-mer ssDNA, but is not able to
stably associate with undamaged 16-mer oligonucleotide (Fig. S4A), Further titration of !
16mtSSB alone or in the presence of ! 80AAG does not result in a distinct binding of the !
16mtSSB to the !A containing 16-mer ssDNA (Fig. S4B). Taken together our results thus
suggest that mtSSB inhibits AAG mediated processing of damaged DNA through direct
protein-protein interaction.
3.5. Inhibition of AAG Activity by mtSSB Occurs Specifically in the Context of Single-
Stranded, but not Double-Stranded DNA
AAG is known to recognize and excise !A lesions from both ssDNA and dsDNA [58]. To
address if mtSSB, inhibits AAG activity on dsDNA as it does in the context of ssDNA, we
performed kinetic experiments. AAG activity was measured under single-turnover
conditions in the absence or presence of ! 16mtSSB, equimolar to the amount of DNA or !
80AAG. Kinetic experiments clearly indicate that while ! 16mtSSB, under equimolar protein
conditions, efficiently inhibits ! 80AAG glycosylase activity on ssDNA, (Fig. 5A, lanes
13-18; and Fig. 5C), it has absolutely no effect the excision of damaged base from dsDNA
substrate (Fig. 5B, lanes 13-18; and Fig. 5D). In the presence of equimolar mtSSB, the
AAG-mediated initial excision rate constant on ssDNA is reduced 1.92-fold, but the activity
rate is unaffected (Table 2). Taken together these findings confirm that the inhibitory effect
observed on ssDNA is a result of protein-protein interaction and further suggest that mtSSB
specifically prevents formation of AP sites within ssDNA that could potentially lead to
formation of harmful DNA breaks. By inhibiting AAG-initiated processing of damaged
bases within ssDNA, mtSSB ensures that lesion removal only occurs upon reestablishment
of dsDNA.
4. Discussion
As a byproduct of energy production in mitochondria, extremely high levels of DNA
damaging species are generated; some of the frequently occurring mtDNA lesions are
products of oxidation and hydrolytic deamination, as well as !-base adducts [4-6]. An
increase in the rate of hydrolytic deamination of adenine to Hx correlates with an increased
likelihood of A → G transition mutations in mtDNA [76]. In addition, high levels of !A in
mtDNA coincide with increased mitochondrial instability and apoptosis [4]. AAG is known
to efficiently recognize and remove both Hx and !A from nuclear DNA. Although
mammalian mitochondrial extracts are able to excise Hx and !-base adducts from DNA, so
far AAG has not been detected in mitochondria [40-42, 77]. Here we report the presence of
AAG in human mitochondrial extracts and propose that mtSSB protein influences AAG-
initiated BER. Upon exposure of cells to MMS we observe a moderate accumulation of
AAG in the mitochondria directly after treatment, while increases in the level of nuclear
AAG occur at later time points (Fig. 1C and S1A). These findings suggest that AAG
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mediated base excision in the mitochondrial genome may occur faster than that in nuclear
DNA. This is in agreement with previous observations that mtDNA lesions are repaired
more rapidly than damages present in the nucleus [78]. In addition, cellular exposure to
oxidizing or alkylating agents gives rise to a higher density of mtDNA lesions compared to
nuclear DNA [7-11], indicating a need to repair mitochondrial damage promptly and
efficiently. In silico analysis of three AAG isoforms predicts the presence of a MTS in two
of them, namely isoforms A and B (Table 1). Accordingly, these two isoforms also have a
high probability to be targeted into mitochondria (Table 1). To confirm localization of both
isoforms A and B in this cellular compartment, understand how is their import regulated, as
well as if localization of these two proteins is timely separated or if they act simultaneously
remains to be addressed in future studies. In order to better understand the function of AAG
isoform A in the mitochondria, we tested whether any mitochondrial protein interacts with
AAG. MtSSB specifically and directly associates with AAG (Fig. 3). The intensity of the
interaction is modulated upon MMS exposure and correlates with the amount of AAG
observed in the mitochondria. As a consequence of direct interaction, ! 16mtSSB inhibits !
80AAG-mediated processing of damaged ssDNA, but has no effect on lesion removal from
the dsDNA (Fig. 5). How the interaction of AAG with mtSSB leads to specific inhibition of
AAG activity within ssDNA and not dsDNA, may potentially be answered at the level of
lesion recognition. In dsDNA, recognition of the damaged nucleotide is a highly organized
process mediated through nucleotide flipping out of the DNA duplex into the active site of
AAG [36]. Due to lack of base pairing and reduced base stacking in ssDNA it has been
suggested that in ssDNA the damaged base is more loosely captured in the AAG active site
[37]. AAG may thereby remove an ! A lesion from ssDNA without tightly binding to it [37].
In the dsDNA however, AAG mediated processing of an ! A lesion occurs through strong
association with the duplex substrate [37]. It is thus possible that by interacting with AAG,
mtSSB prevents lesion recognition, while in dsDNA recognition and removal of the
damaged base is not affected due to tight binding of AAG to damaged dsDNA. Very
recently, mtSSB was reported to associate with another BER glycosylase, UNG1 [44].
Similar to its effect on AAG, mtSSB interacts directly with UNG1 and specifically inhibits
removal of U from ssDNA, but not from dsDNA [44]. Together, these observations suggest
an important role for mtSSB in mitochondrial BER. Besides its involvement in mtDNA
replication, where mtSSB binds and protects large ssDNA regions, mtSSB potentially also
preserves the integrity of smaller ssDNA gaps. Though mtSSB does not efficiently bind to
very short ssDNA, by physically associating and inhibiting DNA glycosylases, mtSSB could
prevent the formation of AP sites and subsequent formation of extremely harmful DNA
breaks in the DNA gaps. Binding of mtSSB to (i) large ssDNA regions generated during
DNA replication, as well as (ii) inhibition of lesion processing within small gaps, through
interaction with DNA glycosylases, are potentially crucial mechanisms for preventing the
formation of DNA breaks, as well counteracting the loss of genetic information [52-55].
MtSSB may thus serve as a BER regulator, ensuring that processing of damaged bases
occurs only upon the reestablishment of dsDNA. Our results suggest the existence of novel
AAG-initiated BER in mitochondria that is regulated by mtSSB. The significance of this
pathway in human cells is demonstrated through finding that targeted overexpression of
AAG in mitochondria strongly sensitizes breast cancer cells to chemotherapeutic agents
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[79]. Future studies are needed to understand the details of AAG-initiated BER in
mitochondria, with a potential to reveal new targets to combat cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abreviations
mtDNA mitochondrial DNA
AAG alkyladenine DNA glycosylase
mtSSB mitochondrial single-stranded binding protein
ROS reactive oxygen species
!A 1,N6-ethenoadenine
AP abasic site
BER base excision repair
pol DNA polymerase
TFAM mitochondrial transcription factor A
APE 1apurinic/apyrimidinic endonuclease 1
MMS methyl methanesulfonate
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• Alkyladenine DNA glycosylase (AAG) localizes to the mitochondria.
• AAG directly interacts with mitochondrial single-stranded binding protein
(mtSSB).
• MtSSB suppresses AAG explicitly in the context of ssDNA, but not dsDNA.
• Interaction between AAG and mtSSB ensures lesion processing within dsDNA.
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Figure 1. Human AAG localizes to the mitochondria, nucleus, and cytoplasm, and its cellular distribution is affected by MMS
treatment
(A) Analysis of human AAG protein distribution in nuclear (N), cytoplasmic (C) and mitochondrial (M) fractions, prepared
from HEK293T cells. Lamin B, Tubulin and mtHSP70 serve as loading control, as well as to ensure purity of the analyzed
fractions. (B) Isolated mitochondria were treated for 1 h with the depicted amounts of trypsin (5, 10, or 20 μg/mL) and analyzed
by immunoblot analysis. In lane 5. before trypsin treatment 0.1% SDS was added. In addition to AAG, we probed for: VDAC1
an outer mitochondrial membrane (OMM) marker, Mitofilin a marker of inner mitochondrial membrane (IMM) and mtHSP70, a
mitochondrial matrix protein. TML represents total mitochondrial lysate obtained from purified mitochondrial fraction. (C)
Immunoblot analysis of endogenous human AAG protein levels in mitochondrial fraction, obtained from mock or 2mM MMS
treated HEK293T cells collected 0, 0.5, 1 or 2h after the treatment. (D) Quantification of AAG protein levels from three
independently performed experiments like the one in (C). Relative AAG protein level is normalized to the level of mtHSP70.
Error-bars represent SD values. (E) and (F) HeLa CCL2 cells synchronized in S-phase by double-thymidine block were
pretreated with 100nM MitoTracker, followed by mock (E) or 2mM MMS (F) treatment. One hour after the treatment cells were
stained with antibody against human AAG. The experiments were performed as described in Experimental Procedures.
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Figure 2. MtSSB is detected in complex with human AAG
(A) Silver staining analysis of human AAG protein complexes purified from mock or 2mM MMS treated HEK293T cells. (B)
Identification of Flag tagged AAG protein in purified fractions from (A) by immunoblot analysis. Arrows indicate the tagged
AAG proteins. (C) LC-MS analysis of mitochondrial proteins that specifically co-purify with AAG. MtSSB is the only
mitochondrial protein specifically identified in human AAG purifications. PCNA, a known-interacting partner of AAG is
depicted as a positive control. The number of unique peptides indicates the number of unique spectra associated with a certain
protein. The experiments were performed as described in Experimental Procedures.
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Figure 3. Human AAG and mtSSB proteins directly interact
(A) Immunoprecipitation of endogenous AAG and mtSSB proteins from extracts prepared from mock (lanes 1 and 2) or 2mM
MMS treated (lanes 3-6) HEK293T cells, by using AAG antibody (lanes 2-6). “M” stands for protein markers. (B)
Recombinant ! 80AAG, BSA and GST-Cdk1 proteins separated by SDS-PAGE, transferred to PVDF membrane and Ponceau
stained. Star next to higher molecular band present in Cdk1 sample designates a contaminant protein co-purifying with Cdk1.
(C) Interaction of ! 80AAG and His-!16mtSSB using far western blotting. Proteins on the PVDF membrane; ! 80AAG, BSA and
GST-Cdk1 were denatured, renatured and then incubated with purified His-! 16mtSSB. After washing, bound protein was
detected with mtSSB antibody. (D) Ponceau staining of recombinant His-!16mtSSB, BSA and His-PCNA proteins separated by
SDS-PAGE and transferred to PVDF membrane. (E) Interaction between ! 80AAG and His-! 16mtSSB assessed by far western
blotting. His-! 16mtSSB, BSA and His-PCNA proteins were denatured, renatured and then incubated with purified ! 80AAG.
After washing, bound protein was detected with AAG antibody. The experiments were performed as described in Experimental
Procedures.
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Figure 4. MtSSB inhibits AAG activity
(A) Schematic representation of 16-mer oligonucleotid used as a substrate in the DNA glycosylase and DNA binding assays.
“X” designates 1,N6-ethenoadenine (!A) lesion. To form dsDNA presented lesion-containing oligo nucleotide was annealed to
the complementary undamaged DNA oligonucleotide. (B) Effect of ! 16mtSSB titration on the ! 80AAG glycosylase activity in
the presence of 2nM !A ssDNA substrate. (C) Quantification of ! 16mtSSB effect on ! 80AAG glycosylase activity from three
independently performed experiments like the one presented in (B) (error-bars represent SD values, *P<0.05). The experiments
were performed as described in Experimental Procedures.
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Figure 5. Inhibition of AAG activity by mtSSB is specific for single-stranded DNA
(A) and (B) Kinetic analysis of ! 80AAG glycosylase activity toward 2nM !A containing ssDNA (A) or dsDNA (B) substrate, in
the absence or presence of ! 16mtSSB. (C) and (D) Quantification of AAG glycosylase activity in the presence of 0nM (!), 2nM
(!) or 200nM (!) ! 16mtSSB, from three independently performed experiments, like the one presented in (A) and (B)
respectively. The experiments were performed as described in Experimental Procedures.
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Table 1
AAG isoforms A and B are potentially targeted to mitochondria
Does isoform contain MTS* Probability of import** MTS**
AAG isoform A YES 09764 MVTPALQMKKPKQFCRR
AAG Isoform B YES 0.9804 MPARSGAQFCRR
AAG isoform C NO 00919 -
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Table 2
Effect of ! 16mtSSB on kinetic constants of ! 80AAG mediated !A lesion excision from
ssDNA and dsDNA
Δ16mtSSB
εA (ssDNA) εA/T (dsDNA)
kobs ± SD(min-1)a initial excision rate (fmol/min)b kobs ± SD(min-1)a initial excision rate (fmol/min)b
0nM 0.0076 ± 0.0011 0.048 0.0233 ± 0.0018 0.488
2nM 0.0074 ± 0.0008 0.041 0.0243 ± 0.0019 0.496
200nM 0.0076 ± 0.0016 0.025 0.0243 ± 0.0018 0.488
aObserved activity rate constants kobs were determined from one-phase exponential association.
b
The initial excision rate value is a result of the rate constant kobs and the maximum saturation cleavage (maxiumum amount of AP product
formed).
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